Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives
Ramon Andrade de Mello, Nathália Moisés Neves, Hakaru Tadokoro, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 11, pp. 3543-3543
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

RNA-based therapies: A cog in the wheel of lung cancer defense
Parvez Κhan, Jawed A. Siddiqui, Imayavaramban Lakshmanan, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 78
Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?
Amol Gupta, Razelle Kurzrock, Jacob J. Adashek
Cancers (2023) Vol. 15, Iss. 5, pp. 1578-1578
Open Access | Times Cited: 17
Molecular Pathology of Lung Cancer
Sinchita Roy‐Chowdhuri
Clinics in Laboratory Medicine (2024) Vol. 44, Iss. 2, pp. 137-147
Closed Access | Times Cited: 5
Drug delivery systems of gefitinib for improved cancer therapy: A review
Deepak Nagdiya, Manish Kumar, Sanchit Arora, et al.
OpenNano (2023) Vol. 14, pp. 100183-100183
Open Access | Times Cited: 13
Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning Approach
Hakan Bozcuk, L. Sert, Kaplan Ma, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 233-233
Open Access
Role of functional genomics in identifying cancer drug resistance and overcoming cancer relapse
Elham Omer Mahgoub, William C. Cho, Majid Sharifi, et al.
Heliyon (2023) Vol. 10, Iss. 1, pp. e22095-e22095
Open Access | Times Cited: 8
Lipid polymer hybrid nanoparticles against lung cancer and their application as inhalable formulation
Seyedeh Negin Kassaee, Derek J. Richard, Godwin A. Ayoko, et al.
Nanomedicine (2024) Vol. 19, Iss. 25, pp. 2113-2133
Closed Access | Times Cited: 3
Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives
Ramon Andrade de Mello, Rafael Voscaboinik, João Vittor Pires Luciano, et al.
Cancers (2021) Vol. 14, Iss. 1, pp. 122-122
Open Access | Times Cited: 19
Molecular Pathology of Lung Cancer
Sinchita Roy‐Chowdhuri
Surgical pathology clinics (2021) Vol. 14, Iss. 3, pp. 369-377
Closed Access | Times Cited: 17
A Novel Algorithm for the Virtual Screening of Extensive Small Molecule Libraries Against ERCC1/XPF Protein-Protein Interaction for the Identification of Therapeutic Resistance-Bypassing Small Anticancer Molecules
Tuğba Gül Inci, Serap Acar, Dilek Turgut‐Balik
TURKISH JOURNAL OF BIOLOGY (2024) Vol. 48, Iss. 2, pp. 112-132
Open Access | Times Cited: 2
Profile of patients with lung cancer at a tertiary care hospital in Nepal: A retrospective analysis
Birendra Kumar Yadav, Alok Thakur, Akash Pradhan, et al.
Cancer Research Statistics and Treatment (2024) Vol. 7, Iss. 4, pp. 396-402
Open Access | Times Cited: 2
Linguistic analysis of plain language summaries and corresponding scientific summaries of Cochrane systematic reviews about oncology interventions
Jelena Šuto, Ana Marušić, Ivan Buljan
Cancer Medicine (2023) Vol. 12, Iss. 9, pp. 10950-10960
Open Access | Times Cited: 6
HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies
Emma Loeffler, Julien Ancel, Véronique Dalstein, et al.
Life (2023) Vol. 14, Iss. 1, pp. 64-64
Open Access | Times Cited: 6
Long non‑coding RNA LINC01748 exerts carcinogenic effects in non‑small cell lung cancer cell lines by regulating the microRNA‑520a‑5p/HMGA1 axis
Yinling Tan, Fengxia Xu, Lingling Xu, et al.
International Journal of Molecular Medicine (2021) Vol. 49, Iss. 2
Open Access | Times Cited: 11
Synergistic antitumor efficacy of PD-1-conjugated PTX- and ZSQ-loaded nanoliposomes against multidrug-resistant liver cancers
Mingjia Gu, Fang Yin, Yuening Qin, et al.
Drug Delivery and Translational Research (2022) Vol. 12, Iss. 10, pp. 2550-2560
Closed Access | Times Cited: 8
Construction of an endoplasmic reticulum stress-related signature in lung adenocarcinoma by comprehensive bioinformatics analysis
Yang Wang, Jun Nie, Ling Dai, et al.
BMC Pulmonary Medicine (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs
Huang‐Chih Chang, C.-C. Wang, Chia‐Cheng Tseng, et al.
Thoracic Cancer (2023) Vol. 14, Iss. 32, pp. 3208-3216
Open Access | Times Cited: 4
Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis
Fu Wenfan, XU Man-man, Shi Xingyuan, et al.
Therapeutic Advances in Chronic Disease (2023) Vol. 14
Open Access | Times Cited: 4
Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma
Mingjing Shen, Kanqiu Jiang, Yiqun Sui, et al.
Lung Cancer (2021) Vol. 160, pp. 84-91
Closed Access | Times Cited: 10
Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors
Chang Liu, Zhenxing Wang, Qian Liu, et al.
Clinical & Translational Oncology (2022) Vol. 24, Iss. 10, pp. 1975-1985
Closed Access | Times Cited: 6
Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic
Massimiliano Cadamuro, Alberto Lasagni, Ángela Lamarca, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 4, pp. 377-388
Open Access | Times Cited: 6
Translation and adaptation of the EORTC QLQ-LC 29 for use in Chinese patients with lung cancer
Wei Dai, Yaqin Wang, Yangjun Liu, et al.
Journal of Patient-Reported Outcomes (2021) Vol. 5, Iss. 1
Open Access | Times Cited: 6
Overexpression and diagnostic significance of INTS7 in lung adenocarcinoma and its effects on tumor microenvironment
Xiang Li, Yiyong Yao, Jinxian Qian, et al.
International Immunopharmacology (2021) Vol. 101, pp. 108346-108346
Closed Access | Times Cited: 6
Tumor Suppressor miR-613 Alleviates Non-Small Cell Lung Cancer Cell via Repressing M2 Macrophage Polarization
Mingjun Yang, Wen Zhou, Mingming Xu, et al.
Journal of Oncology (2023) Vol. 2023, pp. 1-11
Open Access | Times Cited: 2
Disulfidptosis-related lncRNA signatures predict prognosis and immune relevance of lung adenocarcinoma
Wuquan Li, Yong Wang, Yan Lv, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top